Tiansheng Pharmaceutical Group Co Ltd is a China-based company primarily engaged in drug R&D, production, sales, and the cultivation and processing of traditional Chinese medicinal materials. The Company's products include tablets, capsules, granules, teas, pills, and injections. Product varieties cover pediatrics, gynecology, cardiovascular system, digestive system, orthopedics, respiratory medicine, and anti-infective treatment areas. The Company's products are mainly sold to the domestic market.

Employees

1,273

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	CN¥5.080	+0.99%	29,92,550
03/26/03	CN¥5.030	+5.01%	41,37,534
02/26/02	CN¥4.790	+2.79%	27,83,922
01/26/01	CN¥4.660	+3.79%	28,47,950
30/26/30	CN¥4.490	+0.45%	17,79,034

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 06/07/2026			5-day change	1st Jan Change
5.080 ^CNY	+0.99%		+13.65%	+4.53%

08/05	Tiansheng Pharmaceutical Secures Proposed Selection for Three Medicines in China's National Procurement	MT
28/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	161.54Cr 24Cr 21Cr 19Cr 18Cr 34Cr 2.27TCr 34Cr 229.58Cr 89Cr 1.11TCr 89Cr 87Cr 3.86TCr	P/E 2024	-16.5x	P/E 2025	-27.9x
Enterprise Value	169.44Cr 25Cr 22Cr 20Cr 19Cr 35Cr 2.38TCr 36Cr 240.8Cr 94Cr 1.17TCr 94Cr 92Cr 4.05TCr	EV / Sales 2024	2.7x	EV / Sales 2025	3.16x
Free-Float	52.84%	Yield 2024 *	-	Yield 2025	-

08/05	Tiansheng Pharmaceutical Secures Proposed Selection for Three Medicines in China's National Procurement	MT
28/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
28/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/02	Three Tiansheng Pharma Drugs Set to Win Bids for China's Drug Procurement Program	MT
07/11	Tiansheng pharmaceutical and its controlling shareholder penalised, fined	RE
29/25/29	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
14/25/14	Tiansheng Pharmaceutical Group Subsidiaries Tentatively Win Bulk Drug Tenders in Guangdong	MT
15/25/15	Tiansheng Pharmaceutical Gets China Supplementary Drug Approval for Sodium Bicarbonate Injection	MT
27/25/27	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
28/25/28	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/25/28	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/25/10	Tiansheng Pharmaceutical Passes Consistency Evaluation for Antibiotic	MT
26/24/26	Chongqing Pharmaceutical Group Changsheng Pharmaceutical Co., Ltd announced that it expects to receive CNY 60 million in funding from C.Q. Pharmaceutical Holding Co., Ltd., Tiansheng Pharmaceutical Group Co., Ltd.	CI

1 day	+0.99%
1 week	+13.65%
Current month	+13.14%
1 month	-3.05%
3 months	+3.04%
6 months	+3.46%
Current year	+4.53%

Tiansheng Pharmaceutical Group Co., Ltd. Share Price

Stocks

002872

CNE100002QC3

Pharmaceuticals

Valuation: Tiansheng Pharmaceutical Group Co., Ltd.

Chart: Tiansheng Pharmaceutical Group Co., Ltd.

Latest news : Tiansheng Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tiansheng Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4.47	5.11
1 month	4.32	5.26
Current year	4.32	5.65
1 year	4.32	5.81
3 years	3.17	5.97
5 years	3.17	5.99
10 years	3.17	35.18

Manager	Title	Age	Since
Shuang Liu CEO	Chief Executive Officer	33	06/12/2018
Kai Sheng Wang DFI	Director of Finance/CFO	52	23/12/2013
Zonghua Tan PRN	Corporate Officer/Principal	54	11/12/2020

Director	Title	Age	Since
Ding Qing Li BRD	Director/Board Member	63	11/12/2020
Shuang Liu CHM	Chairman	33	06/12/2018
Zonghua Tan BRD	Director/Board Member	54	11/12/2020

	2024	2025
Net sales	57Cr 8.39Cr 7.34Cr 6.76Cr 6.28Cr 12Cr 799.83Cr 12Cr 81Cr 32Cr 392.6Cr 31Cr 31Cr 1.36TCr	51Cr 7.57Cr 6.63Cr 6.1Cr 5.67Cr 11Cr 721.74Cr 11Cr 73Cr 28Cr 354.27Cr 28Cr 28Cr 1.23TCr
Net income	-8.74Cr -1.29Cr -1.13Cr -1.04Cr -96.32L -1.83Cr -122.71Cr -1.85Cr -12Cr -4.83Cr -60Cr -4.83Cr -4.72Cr -208.83Cr	-5.54Cr -81.57L -71.44L -65.8L -61.08L -1.16Cr -78Cr -1.18Cr -7.88Cr -3.07Cr -38Cr -3.06Cr -3Cr -132.42Cr
Net Debt	9.72Cr 1.43Cr 1.25Cr 1.15Cr 1.07Cr 2.03Cr 136.44Cr 2.06Cr 14Cr 5.38Cr 67Cr 5.37Cr 5.25Cr 232.21Cr	7.89Cr 1.16Cr 1.02Cr 93.71L 86.98L 1.65Cr 110.81Cr 1.67Cr 11Cr 4.37Cr 54Cr 4.36Cr 4.27Cr 188.59Cr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIANSHENG PHARMACEUTICAL GROUP CO., LTD.	+0.99%	+13.65%	+6.72%	-1.17%	24Cr
ELI LILLY AND COMPANY	-1.14%	-2.43%	+53.72%	+159.07%	1,07000Cr
JOHNSON & JOHNSON	-1.41%	+0.32%	+66.23%	+60.48%	62TCr
ABBVIE INC.	-2.42%	+0.18%	+34.59%	+85.62%	45TCr
ROCHE HOLDING AG	-0.81%	+0.53%	+31.00%	+25.82%	33TCr
ASTRAZENECA PLC	+1.15%	+0.95%	+39.30%	+40.79%	29TCr
NOVARTIS AG	+0.54%	-0.68%	+28.80%	+48.06%	28TCr
NOVO NORDISK A/S	+2.17%	+4.24%	-25.67%	-38.93%	22TCr
AMGEN INC.	-2.06%	+1.63%	+22.87%	+64.34%	20TCr
GILEAD SCIENCES, INC.	-1.26%	+2.60%	+15.98%	+70.00%	16TCr
Average	+0.40%	+2.28%	+27.35%	+51.41%	36.25TCr
Weighted average by Cap.	+0.70%	+0.77%	+40.21%	+81.69%